Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.
Adverse event
Multiple sclerosis
Neutropenia
Ocrelizumab
Rituximab
Treatment
Journal
Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
20
03
2020
revised:
16
04
2020
accepted:
25
04
2020
pubmed:
30
5
2020
medline:
11
5
2021
entrez:
30
5
2020
Statut:
ppublish
Résumé
Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS). Before approval of this drug, the chimeric anti-CD20 antibody rituximab was used off-label for treatment of MS. On treatment with rituximab late-onset neutropenia (LON) was reported as a rare adverse event. Here we report the case of a patient with MS who first received rituximab without experiencing any hematologic abnormalities, but developed grade IV LON after switching to ocrelizumab. This first case of LON in a patient treated with different anti-CD20 antibodies highlights the necessity of regular hemogram examinations during ocrelizumab.
Identifiants
pubmed: 32470856
pii: S2211-0348(20)30231-5
doi: 10.1016/j.msard.2020.102155
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Immunologic Factors
0
Rituximab
4F4X42SYQ6
ocrelizumab
A10SJL62JY
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102155Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.